Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1575

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 7
Chunk 1575
---
40,000 as of December 31, 2024.

The total amount recorded as due to affiliate
on the consolidated balance sheet as of December 31, 2024 includes the outstanding balance of $15,000 of Administrative Support Fees,
$17,000 of Sponsor Advances, and $40,000 of Second Sponsor Advances, totaling $72,000.

NOTE 5–COMMITMENTS AND CONTINGENCIES 

Registration Rights 

The holders of Founder Shares, Private Placement
Units (including component securities contained therein), and Units (including component securities contained therein) that may be issued
upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement signed prior
to the effective date of the Initial Public Offering, requiring the Company to register such securities for resale. The holders of the
majority of these securities are entitled to make up to two demands, excluding short form demands, that the Company register
such securities. In addition, these holders have certain “piggyback” registration rights with respect to registration statements
filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities
pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration
statements. Chardan may not exercise its demand and “piggyback” registration rights after five and seven years, respectively,
after the effective date of the registration statement of which this prospectus forms a part and may not exercise its demand rights on
more than one occasion.

F-19

OSR HOLDINGS, INC.

(f/k/a Bellevue Life Sciences Acquisition Corp.) 

NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2024

Underwriting Agreement 

The Company granted the
underwriters a 45-day option from the final prospectus relating to the Initial Public Offering to purchase up to 900,000 additional
Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions.

The underwriters were
entitled to an underwriting discount of $0.20 per Unit, or $1,200,000 in the aggregate, equal to 2% of the gross proceeds
of the Initial Public Offering (or $1,380,000 in the aggregate if the underwriters’ over-allotment option is exercised in